[Therapeutic evaluation of 3-(gamma-n-butoxy-beta-carbamyl-oxypropyl)-5-phenyl-5-ethyl-hexahydropyrimidine-2-4-6-one. Clinical and electromyographic studies].
D001463:Barbiturates / Q000627:therapeutic use*; D004576:Electromyography; D006801:Humans; D009069:Movement Disorders / Q000188:drug therapy*; D009132:Muscles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013035:Spasm / Q000188:drug therapy*; D013981:Tic Disorders / Q000188:drug therapy*; D014149:Tranquilizing Agents / Q000627:therapeutic use*; D014202:Tremor / Q000188:drug therapy*
D001463:Barbiturates; D011743:Pyrimidines; D014149:Tranquilizing Agents
Valutazione terapeutica del 3-(gamma-n-butossi-beta-carbamilossi-propil)-5-fenil-5-etil-esaidropirimidina-2-4-6-one. Ricerche cliniche ed elettromiografiche.